CoronaVac and BBIBP‐CorV vaccines against SARS‐CoV‐2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study

Abstract

AbstractPandemic of COVID‐19 hit China at the end of 2022. According to China Center for Disease Control and Prevention, Omicron BA.5.2 and BF.7 were the main circulating variants. Chinese people had a high COVID‐19 vaccination rate, and the most widely used vaccines were CoronaVac (Sinovac) and BBIBP‐CorV (Sinopharm). An online questionnaire was distributed to survey the vaccination history and infection information of China mainland residents during this pandemic. A total of 4250 subjects were included for propensity score matching, 566 unvaccinated subjects and 1072 vaccinated subjects were finally included to analyze the effects of the two vaccines on BA.5.2 and BF.7. The SARS‐CoV‐2 infection rate was 84.5% in the vaccinated group and 82.3% in the unvaccinated group (p = 0.255). Vaccinated subjects had significantly higher rates of COVID‐19‐related symptoms, including fever, cough, nasal obstruction, runny nose, and sore throat. However, vaccinated people had lower risk of pneumonia (odds ratio [OR]: 0.467, 95% confidence interval [CI]: 0.286–0.762) and hospitalization (OR: 0.290, 95% CI: 0.097–0.870) due to COVID‐19. In general, the current study did not observe the protective effect of CoronaVac and BBIBP CorV against BA.5.2 and BF.7 infection. However, these vaccines can still reduce the risk of adverse outcomes such as pneumonia and hospitalization.